229 related articles for article (PubMed ID: 18067883)
1. Invariant chain modulates HLA class II protein recycling and peptide presentation in nonprofessional antigen presenting cells.
Haque A; Hajiaghamohseni LM; Li P; Toomy K; Blum JS
Cell Immunol; 2007 Sep; 249(1):20-9. PubMed ID: 18067883
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
3. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules.
Mukherjee R; Chaturvedi P; Lee-Chan E; Singh B
Mol Immunol; 2008 Apr; 45(8):2166-76. PubMed ID: 18279957
[TBL] [Abstract][Full Text] [Related]
4. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules.
Pathak SS; Blum JS
Traffic; 2000 Jul; 1(7):561-9. PubMed ID: 11208144
[TBL] [Abstract][Full Text] [Related]
5. Processing of an endogenous protein can generate MHC class II-restricted T cell determinants distinct from those derived from exogenous antigen.
Moreno J; Vignali DA; Nadimi F; Fuchs S; Adorini L; Hämmerling GJ
J Immunol; 1991 Nov; 147(10):3306-13. PubMed ID: 1658143
[TBL] [Abstract][Full Text] [Related]
6. The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.
Fujii S; Senju S; Chen YZ; Ando M; Matsushita S; Nishimura Y
Hum Immunol; 1998 Oct; 59(10):607-14. PubMed ID: 9757942
[TBL] [Abstract][Full Text] [Related]
7. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
[TBL] [Abstract][Full Text] [Related]
8. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
9. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
10. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation.
Soos JM; Krieger JI; Stüve O; King CL; Patarroyo JC; Aldape K; Wosik K; Slavin AJ; Nelson PA; Antel JP; Zamvil SS
Glia; 2001 Dec; 36(3):391-405. PubMed ID: 11746775
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
12. MHC class II-associated invariant chain peptide replacement by T cell epitopes: engineered invariant chain as a vehicle for directed and enhanced MHC class II antigen processing and presentation.
Malcherek G; Wirblich C; Willcox N; Rammensee HG; Trowsdale J; Melms A
Eur J Immunol; 1998 May; 28(5):1524-33. PubMed ID: 9603457
[TBL] [Abstract][Full Text] [Related]
13. Cysteinylation of MHC class II ligands: peptide endocytosis and reduction within APC influences T cell recognition.
Haque MA; Hawes JW; Blum JS
J Immunol; 2001 Apr; 166(7):4543-51. PubMed ID: 11254711
[TBL] [Abstract][Full Text] [Related]
14. HLA-DM and the MHC class II antigen presentation pathway.
Jensen PE; Weber DA; Thayer WP; Chen X; Dao CT
Immunol Res; 1999; 20(3):195-205. PubMed ID: 10741860
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules.
Adams S; Humphreys RE
Eur J Immunol; 1995 Jun; 25(6):1693-702. PubMed ID: 7614997
[TBL] [Abstract][Full Text] [Related]
16. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
17. HLA-DM negatively regulates HLA-DR4-restricted collagen pathogenic peptide presentation and T cell recognition.
Amria S; Hajiaghamohseni LM; Harbeson C; Zhao D; Goldstein O; Blum JS; Haque A
Eur J Immunol; 2008 Jul; 38(7):1961-70. PubMed ID: 18506881
[TBL] [Abstract][Full Text] [Related]
18. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
19. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
[TBL] [Abstract][Full Text] [Related]
20. Antigen presentation and T cell development in H2-M-deficient mice.
Fung-Leung WP; Surh CD; Liljedahl M; Pang J; Leturcq D; Peterson PA; Webb SR; Karlsson L
Science; 1996 Mar; 271(5253):1278-81. PubMed ID: 8638109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
